Drug Search Results
More Filters [+]

Chlormezanone

Alternative Names: chlormezanone, trancopal
Latest Update: 2015-10-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GABA Modulator,TSPO Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Approved

Approved Countries: Chile | Germany | India | Ireland | Italy | Lebanon | New Zealand | Pakistan | South Africa | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: Canadian Network for Observational Drug Effect Studies, CNODES
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Chlormezanone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Sclerosis, Relapsing-Remitting

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Q10-12

N/A

Completed

Schizophrenia|Psychotic Disorders|Type 2 Diabetes|Affective Disorders, Psychotic|Bipolar Disorder

2012-12-01

FLORIMS

P2

Completed

Multiple Sclerosis, Relapsing-Remitting

2012-11-26

Recent News Events

Date

Type

Title